Dopamine D 3 receptor Ser9Gly polymorphism and risperidone response

Journal of Clinical Psychopharmacology

Volumn 25, Issue 1, 2005, Pages 6-11

  Lane, Hsien Yuan ^a,b   Hsu, Shih Kuan ^a   Liu, Yi Ching ^a   Chang, Yue Cune ^c   Huang, Chiung Hsien ^a,b   Chang, Wen Ho ^d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TAMKANG UNIVERSITY   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 3 RECEPTOR; RISPERIDONE; DNA; DOPAMINE 2 RECEPTOR; DRD3 PROTEIN, HUMAN; GLYCINE; NEUROLEPTIC AGENT; SERINE;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG ANTAGONISM; DRUG RESPONSE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOSPITALIZATION; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOCIAL STATUS; TREATMENT OUTCOME; AMINO ACID SUBSTITUTION; CHINA; DOSE RESPONSE; GENETICS; METABOLISM; PSYCHOLOGICAL RATING SCALE; SOCIAL BEHAVIOR;

ADULT; AMINO ACID SUBSTITUTION; ANTIPSYCHOTIC AGENTS; CHINA; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; GLYCINE; HUMANS; MALE; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RISPERIDONE; SCHIZOPHRENIA; SERINE; SOCIAL BEHAVIOR;

EID: 12344260363     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000150226.84371.76     Document Type: Article

References (40)

1. Andreasen NC, Flaum M, Swayze VW 2nd, et al. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch Gen Psychiatry. 1990;47:615-621.
2. Meltzer HY, Park S, Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc Natl Acad Sci USA. 1999;96:13591-13593.
3. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50:873-883.
4. 2A receptor gene. Am J Psychiatry. 2002;159:1593-1595.
5. 4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry. 1994;51:912-917.
6. 3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res Rev. 2000;31:277-287.
7. 3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther. 1995;275:1239-1246.
8. 3 and autoreceptor preferring antagonist (-)-DS121 on locomotor activity, conditioned place preference and intracranial self-stimulation in the rat. Behav Pharmacol. 1995;6:107-115.
9. 2 receptors. Neuron. 1997;19:837-848.
10. 3 receptor selective RGH-1756. Neuropharmacology. 2001;40:383-393.
11. Heidbreder CA, Foxton R, Cilia J, et al. Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation. Psychopharmacology. 2001;156:338-351.
12. Ishiguro H, Okuyama Y, Toru M, et al. Mutation and association analysis of the 5′ region of the dopamine D3 receptor gene in schizophrenia patients: identification of the Ala38Thr polymorphism and suggested association between DRD3 haplotypes and schizophrenia. Mol Psychiatry. 2000;5:433-438.
13. Anney RJ, Rees MI, Bryan E, et al. Characterisation, mutation detection, and association analysis of alternative promoters and 5′ UTRs of the human dopamine D3 receptor gene in schizophrenia. Mol Psychiatry. 2002;7:493-502.
14. 3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry. 1999;4:247-253.
15. 9Gly polymorphism. Neuropsychopharmacology. 2002;27:105-119.
16. 3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology. 1999;21:17-27.
17. Steen VM, Lovlie R, MacEwan T, et al. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry. 1997;2:139-145.
18. 3 receptor gene and schizophrenia. Am J Med Genet. 1997;74:40-43.
19. 9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry. 1998;3:72-75.
20. 4) receptors in schizophrenia. Biol Psychiatry. 1996;40:1209-1217.
21. 3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol. 1999;10:17-20.
22. Shaikh S, Collier DA, Sham PC, et al. Allelic association between a Ser9Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet. 1996;97:714-719.
23. Malhotra AK, Goldman D. Benefits and pitfalls encountered in psychiatric genetic association studies. Biol Psychiatry. 1999;45:544-550.
24. Staddon S, Arranz MJ, Mancama D, et al. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology. 2002;162:18-23.
25. American Psychiatric Association. Structured Clinical Interview for DSM-IV. Washington, DC: American Psychiatric Press; 1994.
26. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
27. Lane HY, Chiu WC, Chou JCY, et al. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry. 2000;61:209-214.
28. Honigfeld G, Klett G. The Nurses' Observation Scale for Inpatients Evaluation: a new scale for measuring improvement in chronic schizophrenia. J Clin Psychol. 1965;21:65-71.
29. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry. 1988;45:789-796.
30. Chouinard G, Ross-Chouinard A, Annable L, et al. The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci. 1980;7:33.
31. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive ration scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
32. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049-1060.
33. 3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun. 1996;225:1068-1072.
34. Strauss JS, Carpenter WT Jr. The prediction of outcome in schizophrenia: I. Characteristics of outcome. Arch Gen Psychiatry. 1972;27:739-746.
35. Szymanski S, Lieberman J, Pollack S, et al. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry. 1996;39:249-254.
36. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(suppl 9):5-9.
37. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull. 1990;16:185-194.
38. 2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J Clin Psychopharmacol. 2002;22:622-624.
39. Darby JK, Pasta DJ, Elfand L, et al. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol. 1997;17:478-484.
40. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology. 2002;161:263-270.